Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ANGLE in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$1.89.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in ANGLE. This N/A consensus rating has held steady for over two years.
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
Read More